Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

<p>Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking presentation […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/pliant-therapeutics-integris-psc-phase-2a-interim-data-evaluating-bexotegrast-in-primary-sclerosing-cholangitis-to-be-highlighted-in-an-oral-late-breaking-presentation-at-the-liver-meeting-2023/">Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>